Sectoral Asset Management, an investment company, led a $83.5m Series A funding round in LENZ Therapeutics, a biopharmaceutical company. “People with presbyopia are looking for a product that is highly effective in improving near vision and lasts their entire workday. We’re pleased to have assembled this strong group of investors as we seek to bring such a product to market. The strong interest in our financing clearly reflects the opportunity for an eye drop to treat presbyopia,” Eef Schimmelpennink, LENZ President and CEO.